Contribute to the health of everyone in the biological pharmaceuticals : KAKETSUKEN

17 January 2011 ：KAKETSUKEN obtained the marketing approval of the Cell Culture-derived Japanese encephalitis vaccine (inactivated)

12 January 2011 ：KAKETSUKEN Awarded HHS Contract Valued at up to Million for the Development of a Live Attenuated Smallpox Vaccine (LC16m8)

01 January 2011 ：Message from Top Management

01 January 2011 ：Mission

01 January 2011 ：Corporate Summary

Our daily efforts towards acquiring advanced technologies in order to protect human health

Corporate history, list of directors, articles of incorporation, branch offices/affiliate corporations, business report, and settlement of accounts

Creating new potential for manufacturing vaccines and preventing communicable diseases, utilizing our advanced technologies

Focusing on the "prevention" of diseases which is a positive healthcare field, and aiming to be the world's top-ranked firm in the biotechnology field.